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Abstract
BACKGROUND—Complementary and alternative medicine is frequently used in the 
management of chronic pediatric diseases, but little is known about its use by those with 
Duchenne or Becker muscular dystrophy.
METHODS—Complementary and alternative medicine use by male patients with Duchenne or 
Becker muscular dystrophy and associations with characteristics of male patients and their 
caregivers were examined through interviews with 362 primary caregivers identified from the 
Muscular Dystrophy Surveillance, Tracking, and Research Network.
RESULTS—Overall, 272 of the 362 (75.1%) primary caregivers reported that they had used any 
complementary and alternative medicine for the oldest Muscular Dystrophy Surveillance, 
Tracking, and Research Network male in their family. The most commonly reported therapies 
were from the mind-body medicine domain (61.0%) followed by those from the biologically based 
practice (39.2%), manipulative and body-based practice (29.3%), and whole medical system 
(6.9%) domains. Aquatherapy, prayer and/or blessing, special diet, and massage were the most 
frequently used therapies. Compared with nonusers, male patients who used any therapy were 
more likely to have an early onset of symptoms and use a wheel chair; their caregivers were more 
likely to be non-Hispanic white. Among domains, associations were observed with caregiver 
education and family income (mind-body medicines [excluding prayer and/or blessing only] and 
whole medical systems) and Muscular Dystrophy Surveillance, Tracking, and Research Network 
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site (biologically based practices and mind-body medicines [excluding prayer and/or blessing 
only]).
CONCLUSIONS—Complementary and alternative medicine use was common in the 
management of Duchenne and Becker muscular dystrophies among Muscular Dystrophy 
Surveillance, Tracking, and Research Network males. This widespread use suggests further study 
to evaluate the efficacy of integrating complementary and alternative medicine into treatment 
regimens for Duchenne and Becker muscular dystrophies.
Keywords
Becker muscular dystrophy; complementary therapies; Duchenne muscular dystrophy; 
neuromuscular diseases
Introduction
Complementary and alternative medicine (CAM) has traditionally been described as medical 
practices and use of therapies not regarded as conventional medicine. Currently the National 
Center for Complementary and Alternative Medicine endorses the term “complementary 
health approaches” to describe those medical practices and products used to manage 
disease.1 The evolving views can complicate studies of CAM use because of changes in 
definitions and designations of certain therapies as CAM. Historically, estimates of CAM 
use in different countries have ranged from 9% to 73%.2 A recent US survey estimated that 
one in nine children used some form of CAM,3 and other US studies observed CAM use 
was higher among children with chronic conditions.4-14 In addition, disease prognosis and 
severity,4,5 as well as caregiver characteristics,11-14 have been found to influence CAM use 
in children.
Although some CAM therapies have been increasingly used in pediatric populations, little 
data exist regarding CAM use among those affected with Duchenne or Becker muscular 
dystrophy. Samdup et al.15 conducted a clinic-based study among Canadian children with 
chronic medical conditions and observed three of 15 (20%) with Duchenne muscular 
dystrophy used CAM. A study using data from a population-based cohort of male patients 
with Duchenne or Becker muscular dystrophy identified by the Muscular Dystrophy 
Surveillance, Tracking, and Research Network (MD STARnet) estimated that 80% of 
families used CAM for their children.16 This analysis also evaluated the impact of care-giver 
characteristics on CAM use and observed caregivers who reported use of whole medical 
system therapies for their childrenwere more likely to have college education and a higher 
family income.16
With clinical trials investigating the effectiveness of novel therapies for Duchenne and 
Becker muscular dystrophies increasingly being implemented,17,18 information related to 
patient characteristics and CAM use is important to monitor interactions between CAM and 
therapies being tested. In recent years, the MD STARnet has expanded the number of 
participating sites and correspondingly, the available data from this well-described cohort. 
Using data from this expanded population, the objectives of the present study were to 
estimate CAM use by the oldest affected male in each MD STARnet family and to 
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investigate associations between CAM use and characteristics of these male patients and 
their primary caregivers.
Methods
The MD STARnet is a multisite, population-based study initiated in 2002 to identify 
individuals diagnosed with Duchenne or Becker muscular dystrophy born on or after 
January 1, 1982 through December 31, 2011 and residing in Arizona, Colorado, Iowa, or 12 
counties in western New York State. The MD STARnet was expanded to Georgia in 2005 
and Hawaii in 2008. The surveillance methodology developed for the MD STARnet has 
been described elsewhere.19 A committee of neuromuscular clinicians experienced in 
treating patients with Duchenne or Becker muscular dystrophy reviewed medical record data 
collected by trained abstractors and assigned a case status (definite, probable, possible, 
asymptomatic, or affected female) to each individual as detailed elsewhere.20
Interview data collection
Primary caregivers of MD STARnet males with definite or probable case status were invited 
to participate in a structured interview developed by MD STARnet investigators to examine 
socioeconomic and acculturation factors, social support, early development, clinical 
outcomes, and use of CAM, medical services, and assistive devices. A systematic 
recruitment protocol was used to obtain caregiver consent to conduct the interview. The 
interview protocol was approved by the institutional review board at each MD STARnet 
site.
Interview items for CAM use were based on previous studies.21,22 Primary caregivers were 
asked if the MD STARnet male had ever used a CAM therapy read from a prespecified list. 
If the therapy was used, caregivers were asked if it was recommended by a health care 
provider. Caregivers were also asked to report use of any additional CAM therapies not 
listed and if these therapies were recommended by a health care provider. Because a major 
source of CAM information is obtained from friends and family members,23 CAM use by 
multiple MD STARnet males from the same family is likely to be correlated; thus, only the 
data from the oldest affected male in each family were included in the current analysis. Data 
from Hawaii were excluded because there were only two caregiver participants from that 
state.
Statistical analysis
CAM use was examined by selected characteristics of MD STARnet males and their 
primary caregivers. Characteristics of males examined were disease phenotype, use of wheel 
chairs or noninvasive positive pressure ventilation devices, vital status, and number of years 
since disease diagnosis. Disease phenotype was based on the age of onset of symptoms. If 
symptoms occurred before the sixth birthday, disease was classified as early onset, 
otherwise it was classified as late onset.16 The number of years since disease diagnosis was 
calculated as the difference between age at interview and age at diagnosis. If the male was 
deceased at the time of interview, the age at death was used instead of the age at interview. 
Caregiver characteristics examined were age at interview, race and ethnicity, marital status 
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(if the caregiver was the biological parent), education, family income, and MD STARnet 
site.
SAS 9.3 (SAS Institute, Cary, NC) was used for statistical analysis. To allow comparisons 
with a previous study of CAM use in the MD STARnet population,16 CAM therapies 
reported by the caregiver were classified into the following domains: biologically based 
practices (herbs, special diet, megavitamins, and glycoproteins); manipulative and body-
based practices (massage, chiropractic manipulation, and osteopathic manipulation); mind-
body medicine (aquatherapy, hippotherapy, self-hypnosis, prayer and/or blessings, and 
companion animals); whole medical systems (acupuncture and homeopathy); and other. 
Additional analyses were conducted for special diet, massage, and aquatherapy individually. 
These were the most commonly reported CAM therapies used in the previous MD STARnet 
analysis.16 Because of the debate of whether prayer and/or blessing is recognized as a CAM 
therapy,3,6 separate analyses were performed for the mind-body medicine domain with and 
without caregivers who only reported use of prayer and/or blessing in that domain.
For users and nonusers in each CAM domain, the chi-square test or Fisher exact test was 
used to compare categorical characteristics of MD STARnet males and primary caregivers. 
The t test was used to compare continuous variables. For each test, P < 0.05 was considered 
to be statistically significant. Because CAM therapies reported by a caregiver could be from 
multiple domains, the observations across domains did not necessarily represent independent 
caregivers. Given that this is a descriptive analysis, adjustment for multiple comparisons 
was not made. Additionally, there is controversy in whether to adjust for multiple 
comparisons in epidemiologic studies, and in which methods to apply.24-26
Results
Overall, 362 primary caregivers completed the interview. Using the American Association 
for Public Opinion Research calculator,27 the response rate was 53% and the cooperation 
rate was 66%. Surveillance data were used to compare characteristics of caregiver 
participants and the oldest MD STARnet males with those of all eligible caregivers and 
oldest males. A statistically significant difference was observed for MD STARnet site (P = 
0.02), but not for vital status, year of birth, or parental race and ethnicity and education (P > 
0.05) (data not revealed).
CAM use
Of the 362 participants, 272 (75%) reported any CAM use by their oldest MD STARnet 
male. The total number of individual CAM therapies reported by caregivers ranged from 1 
to 12; 87 (32%) reported one therapy, 77 (28%) reported two therapies, 44 (16%) reported 
three therapies, and 64 (24%) reported four or more CAM therapies (data not revealed). 
Aquatherapy, prayer and/or blessing, special diet, and massage were the most frequently 
used CAM therapies (Table 1). When examined by domains, therapies in the mind-body 
medicine domain were the most commonly reported by primary caregivers (61.0%), 
followed by those in the biologically based practice (39.2%), manipulative and body-based 
practice (29.3%), and whole medical system domains (6.9%). Also, 32 caregivers (8.8%) 
reported use of other CAM therapies, which included equine therapy, Haelan therapy, yoga, 
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reiki, fire cupping, gwa sha, Qi gong, and electrotherapy, as well as coenzyme Q10, creatine, 
and melatonin supplement use (data not revealed). Overall, 170 (47%) male patients had 
used at least one CAM therapy recommended by a health care provider (data not revealed); 
special diet and aquatherapy were the most frequently recommended therapies.
Associations between CAM use and characteristics of MD STARnet males and primary 
caregivers
Compared with nonusers, MD STARnet males who used any CAM were more likely to be 
classified with the early-onset phenotype (P < 0.05) and using a wheel chair (P < 0.05); no 
statistically significant associations were observed for other characteristics (Table 2). 
Similar results were observed when CAM use was examined by individual domains, except 
for the association between wheel chair use and users of manipulative and body-based 
practice therapies (P = 0.059, data not revealed), and the associations between disease 
phenotype and wheel chair use among users of whole medical system therapies (P > 0.05). 
Among the most frequently reported CAM therapies, massage users were more likely to use 
a wheel chair (P < 0.01), and a larger proportion of aquatherapy users had the early-onset 
phenotype (P < 0.01) or used a wheel chair (P < 0.01); no significant associations were 
observed between use of a special diet and any male characteristic examined.
A statistically significant association was observed between any CAM use and primary 
caregiver race and ethnicity; caregivers of CAM users were more likely to be non-Hispanic 
white than caregivers of nonusers (P < 0.05) (Table 3). Similar associations were observed 
for the domains of biologically based practices, mind-body medicine (with or without prayer 
and/or blessing), and whole medical systems (P < 0.05). Comparison of users and nonusers 
by individual CAM domains revealed that caregivers of MD STARnet males who used 
biologically based practice therapies were more likely to reside in Arizona (P < 0.05); those 
caregivers of male patients who used mind-body medicine therapies (excluding prayer 
and/or blessing only) had higher education levels, higher family income, or were more likely 
to reside in New York State (P < 0.05); and those caregivers of male patients who used 
whole medical system therapies were more likely to have higher education and higher 
family income (P < 0.01). Also, a larger percentage of caregivers of male patients who used 
special diet resided in Arizona (P < 0.01); caregivers of male patients who used aquatherapy 
were more likely to be non-Hispanic white (P < 0.05), reside in New York State (P < 0.01), 
and have higher family incomes (P < 0.05). No significant associations were observed 
between caregiver characteristics and massage therapy use among MD STARnet males.
Discussion
The present study estimated that 75% of MD STARnet primary caregivers reported CAM 
use by their oldest affected male. This was greater than previous reports of 20% among 
children with Duchenne muscular dystrophy15 and 44% among children with neurological 
disorders.28 These differences could be explained in part by whether current use or lifetime 
use was investigated, whether the study was clinic-based or population-based, and the 
number and type of CAM therapies examined.
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The present study also observed that 47% of MD STARnet males had used at least one 
CAM therapy recommended by a health care provider. Such data were not collected in 
previous studies of children with Duchenne muscular dystrophy15 or neurological 
disorders,28 although a survey conducted in a large US metropolitan children's hospital 
reported that 67% of pediatricians recommended CAM to their patients.10 This difference 
may be due in part to the variability in practice approaches across MD STARnet sites 
compared with potentially less variable approaches within one children's hospital.
Aquatherapy was the most frequently recommended CAM in the present study. This may be 
due in part to possible beneficial effects of such therapy on motor function in children29 and 
the movement toward its acceptance as a conventional therapy.30 Special diet (e.g., low-
calorie or low-fat diet) was another commonly recommended CAM therapy for MD 
STARnet males. The use of aquatherapy and special diet has been recommended as part of 
standard clinical management of Duchenne muscular dystrophy.31 As the most commonly 
recommended CAM therapies in the MD STARnet population, the efficacy of aquatherapy 
and special diet in modifying symptom severity and rate of disease progression requires 
further investigation.
Consistent with studies that reported associations between CAM use and disease 
severity,5,15,32 the present study found MD STARnet males with early onset of symptoms 
and who used a wheel chair were more likely to use CAM. Some studies suggested that 
parental demographic characteristics, such as age,12 race and ethnicity,13,23 
education,11,15,23,32 and family income,5 influence CAM use among pediatric patients, but 
these findings were not supported in other studies.9,28,33 The present study did suggest that 
associations with caregiver characteristics were domain specific. For example, caregiver 
education and family income were not significantly associated with any CAM use; however, 
caregivers with a higher education and higher family income were more likely to report use 
of whole medical system therapies and mind-body medicine (excluding prayer and/or 
blessing) therapies by MD STARnet males. The cost of these latter therapies and the 
differences in coverage of such costs by third-party payers may partly explain the observed 
associations. Differences in CAM use by MD STARnet site were significant for biologically 
based practice and mind-body medicine (excluding prayer and/or blessing) therapies. 
Similarities in provider recommendations within sites may have contributed to these 
associations.
Findings from this descriptive study should be interpreted cautiously. With a response rate 
of 53%, findings of CAM use may not generalize to the total MD STARnet population, 
although selected characteristics of primary care-givers and oldest affected males among the 
participants were similar to those among all eligible caregivers and oldest affected males. 
Primary caregiver reports of life-time CAM use could be subject to underreporting; 
however, the number of years since disease diagnosis and time at interview was similar 
between CAM users and nonusers. Caregivers might also have underreported dietary 
supplements other than herbs, vitamins, or minerals, because such response choices were not 
provided in the interview. Moreover, a parent's personal experience with CAM has been 
reported to be significantly associated with CAM use in their children.7,11,14,28,32 In the 
current study, data were not available to evaluate the impact of parental personal experience 
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with CAM. Additionally, the reported use of certain therapies, such as osteopathic 
manipulation and acupuncture, was low, which could reflect the lack of specialists who 
provide these treatments. Without knowing the availability of specialists in the surveillance 
areas, it is difficult to evaluate why use of certain therapies is so low. Despite these 
limitations, the strengths of this study are the use of a cohort of males identified by 
systematic, population-based medical record review,19 detailed case definitions assigned by 
neuromuscular clinicians,20 and the large sample of primary caregivers.
It is important to note that the designation of a certain therapy as CAM is evolving over 
time, as is the approach to classifying types of CAM into broader domains. Currently, the 
NCCAM describes CAM therapies as “complementary health approaches” of which they 
identify two subgroups, “natural products,” and “mind and body practices”.1 Although the 
present study classified CAM therapies into domains previously recognized by the NCCAM, 
the constructed domains are consistent with current NCCAM groupings, while providing 
greater specificity of therapy types. Retaining this greater specificity seemed an appropriate 
approach considering emerging views of certain therapies as conventional medicine.
In summary, the present study observed high estimates of CAM use in disease management 
among MD STARnet males. Further studies are recommended to evaluate efficacy of CAM 
therapies being integrated into conventional treatment regimens.
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TABLE 1
Reported Use of Complementary and Alternative Medicine in Male Patients With Duchenne or Becker 
Muscular Dystrophy, Muscular Dystrophy Surveillance, Tracking, and Research Network
CAM Domain and/or Therapy Use Provider Recommended
n (%)* n (%)†
Biologically based practices‡ 142 (39.2) 81 (57.0)
    Herbs, mouth 61 (16.9) 16 (26.2)
    Herbs, skin 25 (6.9) 3 (12.0)
    Special diet 78 (21.5) 56 (71.8)
    Megavitamins 29 (8.0) 16 (55.2)
    Glycoproteins 11 (3.0) 1 (9.1)
Manipulative and body-based‡ 106 (29.3) 29 (27.4)
    Massage 78 (21.5) 29 (37.2)
    Chiropractic manipulation 54 (14.9) 6 (11.1)
    Osteopathic manipulation 10 (2.8) 2 (20.0)
Mind-body medicine‡ 221 (61.0) 99 (44.8)
    Aquatherapy 136 (37.6) 89 (65.4)
    Hippotherapy 48 (13.3) 16 (33.3)
    Self-hypnosis 2 (0.6) 0 (0.0)
    Prayer and/or blessings 126 (34.8) 2 (1.6)
    Companion animals 21 (5.8) 2 (9.5)
Whole medical systems‡ 25 (6.9) 5 (20.0)
    Acupuncture 7 (1.9) 2 (28.6)
    Homeopathy 21 (5.8) 4 (19.0)
Other 32 (8.8) 17 (53.1)
Abbreviation:
CAM = Complementary and alternative medicine
*
Denominator used to calculate the percentage is the number of male patients with Duchenne or Becker muscular dystrophy included in this study 
(n = 362).
†
Denominator used to calculate the percentage is the number of users for each specific CAM therapy or domain.
‡
Total number of users for each CAM domain was less than sum of the number of users for individual CAM therapies within the domain because 
of the use of more than one CAM therapy.
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TABLE 2
Comparison of Selected Characteristics of Male Patients With Duchenne or Becker Muscular Dystrophy by 
Complementary and Alternative Medicine Use, Muscular Dystrophy Surveillance, Tracking, and Research 
Network
Characteristic
Nonusers (n = 
90)
Any CAM (n = 
272)
CAM Domains
Biologically Based 
Practices (n = 
142)
Manipulative and 
Body-Based 
Practices (n = 106)
Mind-Body 
Medicine (n = 
221)
Disease Phenotype*
    Early onset 69 (76.7) 232 (85.6) 123 (87.2) 92 (87.6) 192 (87.3)
    Late onset 21 (23.3) 39 (14.4) 18 (12.8) 13 (12.4) 28 (12.7)
Number of years since diagnosis 9.4 ± 5.7 9.9 ± 5.7 10.0 ± 5.9 10.0 ± 5.8 10.0 ± 5.6
Used wheel chair†
    Yes 52 (59.8) 201 (73.9) 105 (73.9) 77 (72.6) 169 (76.5)
    No 35 (40.2) 71 (26.1) 37 (26.1) 29 (27.4) 52 (23.5)
Age first used wheel chair (yr) 9.9 ± 2.9 9.3 ± 2.6 9.1 ± 2.4 9.2 ± 2.4 9.5 ± 2.7
Used NIPPVD
    Yes 20 (23.0) 70 (25.9) 37 (26.4) 29 (27.6) 60 (27.4)
    No 67 (77.0) 200 (74.1) 103 (73.6) 76 (72.4) 159 (72.6)
Age first used NIPPVD (yr) 16.1 ± 3.4 15.0 ± 3.3 14.5 ± 3.4 15.5 ± 3.3 14.9 ± 3.2
Vital status at interview
    Living 79 (87.8) 251 (92.3) 133 (93.7) 97 (91.5) 204 (92.3)
    Deceased 11 (11.2) 21 (7.7) 9 (6.3) 9 (8.5) 17 (7.7)
CAM Domains CAM Therapies
Mind-Body (Excluding Prayer 
and/or Blessing Only) (n = 160)
Whole Medical Systems (n 
= 25)
Special Diet (n = 78) Massage (n = 78) Aquatherapy (n = 136)
143 (89.4) 20 (83.3) 66 (84.6) 67 (85.9) 121 (89.0)
17 (10.6) 4 (16.7) 12 (15.4) 11 (14.1) 15 (11.0)
10.0 ± 5.7 9.7 ± 5.5 10.0 ± 5.8 10.3 ± 5.7 9.9 ± 5.7
125 (78.1) 19 (76.0) 56 (71.8) 62 (79.5) 107 (78.7)
35 (21.9) 6 (24.0) 22 (28.2) 16 (20.5) 29 (21.3)
9.6 ± 2.9 9.6 ± 2.2 9.2 ± 2.7 9.4 ± 2.6 9.5 ± 2.9
44 (27.9) 5 (20.0) 22 (28.6) 19 (24.7) 36 (26.9)
114 (72.2) 20 (80.0) 55 (71.4) 58 (75.3) 98 (73.1)
14.6 ± 3.3 13.8 ± 2.4 14.7 ± 3.7 15.9 ± 3.0 14.4 ± 3.2
147 (91.9) 24 (96.0) 74 (94.9) 71 (91.0) 124 (91.2)
13 (8.1) 1 (4.0) 4 (5.1) 7 (9.0) 12 (8.8)
Abbreviations:
CAM = Complementary and alternative medicine
NIPPVD = Noninvasive positive pressure ventilation devices
Categorical variables were presented as N (%) and analyzed by the chi-square test or Fisher exact test; continuous variables were presented as 
mean ± standard deviation and analyzed by the t test. Nonusers were the comparison group. Because of missing values, the total for some 
categories may not match; because of rounding, percentages may not total 100.
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*Significant associations between disease phenotype and use of any CAM (P < 0.05), biologically based practices (P < 0.05), manipulative and 
body-based practices (P < 0.05), mind-body medicine (with or without prayer and/or blessings only) (P < 0.05), and aquatherapy (P < 0.05).
†Significant associations between wheel chair use and use of any CAM (P < 0.05), biologically based practices (P < 0.05), mind-body medicine 
(with or without prayer and/or blessings only) (P < 0.01), massage (P < 0.01), and aquatherapy (P < 0.01).
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